Evidence map›Paper›PMID 41727556›Full record

ReviewBritish journal of biomedical science2026

Antimicrobial Resistance: The Answers.

Beverley C Millar, Mary J Cates, Marco S Torrisi, Amanda J Round, Aisling Warde, Colm J Lowery, John E Moore

Abstract readReview
In one paragraph

Review in British journal of biomedical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Beverley C MillarNorthern Ireland Public Health Laboratory, Belfast City Hospital, Belfast, Northern Ireland, United Kingdom.
Mary J CatesSchool of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, United Kingdom.
Marco S TorrisiSchool of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, United Kingdom.
Amanda J RoundSchool of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, United Kingdom.
Aisling WardeSchool of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, United Kingdom.
Colm J LowerySchool of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, United Kingdom.
John E MooreNorthern Ireland Public Health Laboratory, Belfast City Hospital, Belfast, Northern Ireland, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) has caused a global public health crisis, contributing to approximately five million deaths in 2019 and predicted deaths of approximately ten million annually by 2050. This equates to approximately 1.4-fold more deaths annually from AMR in 2050 than the entire COVID-19 pandemic to date. To tackle this AMR pandemic, regulatory and policy frameworks have been prepared at local, national and international levels with multi-faceted proposals and advances encompassing surveillance, diagnostics, infection prevention, antibiotic prescribing and variation of existing and novel treatment approaches. This narrative review primarily focuses on research and development which have been documented over the last five years in relation to therapeutic approaches at various stages in clinical development and the potential role that vaccines can play in the fight against AMR. This review provides an overview on antibacterial drugs, including novel classes of antibiotics, which have been recently approved, as well as combination antibiotic therapy and the potential of repurposed drugs. The potential role of novel antimicrobial, antibiofilm and quorum sensing inhibitors, such as antimicrobial peptides, nanomaterials and compounds from the extreme and natural environments, as well as ethnopharmacology including the antimicrobial effects of plants, spices, honey and venoms are explored. Novel therapeutic approaches are critically discussed in terms of their realistic clinical potential, detailing recent and ongoing trials to highlight the current interest of these approaches, including immunotherapy, bacteriophage therapy, antimicrobial photodynamic therapy (aPDT), antimicrobial sonodynamic therapy (aSDT), nitric oxide therapy and microbiome manipulation including faecal microbiota transplantation (FMT). The potential of predatory bacteria as living antimicrobial agents is also discussed. Importantly, there have been many technological developments which have enhanced bioprospecting and research and development of novel antimicrobials which this review draws attention to, including artificial intelligence, machine learning and Organ-on-a-Chip devices. Finally, key messages from the recent World Health Organization report into the role of vaccines against AMR provides an interesting perspective relating to prevention which can be of significance in tackling the AMR burden.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsDrug Resistance, BacterialDrug Resistance, MicrobialBetacoronavirusCOVID-19HumansPandemicsSARS-CoV-2Anti-Bacterial Agentsantibioticantibiotic resistanceantimicrobial resistance (AMR)bacteriophage therapycystic fibrosisinnovationnew approachespolicy

Identifiers

PMID41727556
PMCPMC12922517

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.